JP2020517295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517295A5 JP2020517295A5 JP2019558623A JP2019558623A JP2020517295A5 JP 2020517295 A5 JP2020517295 A5 JP 2020517295A5 JP 2019558623 A JP2019558623 A JP 2019558623A JP 2019558623 A JP2019558623 A JP 2019558623A JP 2020517295 A5 JP2020517295 A5 JP 2020517295A5
- Authority
- JP
- Japan
- Prior art keywords
- module
- receptor
- ligand
- target
- immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002865 immune cell Anatomy 0.000 claims 23
- 239000003446 ligand Substances 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108020003175 receptors Proteins 0.000 claims 10
- 102000005962 receptors Human genes 0.000 claims 10
- 230000005754 cellular signaling Effects 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 108091008874 T cell receptors Proteins 0.000 claims 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 4
- 230000000139 costimulatory effect Effects 0.000 claims 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 3
- -1 CD3ζ Proteins 0.000 claims 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000002519 immonomodulatory effect Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000000087 stabilizing effect Effects 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 210000004990 primary immune cell Anatomy 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000035025 signaling receptors Human genes 0.000 claims 2
- 108091005475 signaling receptors Proteins 0.000 claims 2
- 230000006641 stabilisation Effects 0.000 claims 2
- 238000011105 stabilization Methods 0.000 claims 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 2
- 101710145634 Antigen 1 Proteins 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- 102100037904 CD9 antigen Human genes 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102100032530 Glypican-3 Human genes 0.000 claims 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims 1
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101710160107 Outer membrane protein A Proteins 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- 229940126546 immune checkpoint molecule Drugs 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000007115 recruitment Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023216495A JP2024038039A (ja) | 2017-04-26 | 2023-12-22 | キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762490578P | 2017-04-26 | 2017-04-26 | |
| US201762490580P | 2017-04-26 | 2017-04-26 | |
| US201762490576P | 2017-04-26 | 2017-04-26 | |
| US62/490,580 | 2017-04-26 | ||
| US62/490,576 | 2017-04-26 | ||
| US62/490,578 | 2017-04-26 | ||
| PCT/US2018/029218 WO2018200583A1 (en) | 2017-04-26 | 2018-04-24 | Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023216495A Division JP2024038039A (ja) | 2017-04-26 | 2023-12-22 | キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517295A JP2020517295A (ja) | 2020-06-18 |
| JP2020517295A5 true JP2020517295A5 (enExample) | 2021-06-10 |
| JP7538601B2 JP7538601B2 (ja) | 2024-08-22 |
Family
ID=63918704
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558623A Active JP7538601B2 (ja) | 2017-04-26 | 2018-04-24 | キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用 |
| JP2019558421A Pending JP2020517287A (ja) | 2017-04-26 | 2018-04-24 | キメラ抗体／ｔ細胞受容体構築物及びその使用 |
| JP2023051860A Pending JP2023093472A (ja) | 2017-04-26 | 2023-03-28 | キメラ抗体／ｔ細胞受容体構築物及びその使用 |
| JP2023216495A Withdrawn JP2024038039A (ja) | 2017-04-26 | 2023-12-22 | キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558421A Pending JP2020517287A (ja) | 2017-04-26 | 2018-04-24 | キメラ抗体／ｔ細胞受容体構築物及びその使用 |
| JP2023051860A Pending JP2023093472A (ja) | 2017-04-26 | 2023-03-28 | キメラ抗体／ｔ細胞受容体構築物及びその使用 |
| JP2023216495A Withdrawn JP2024038039A (ja) | 2017-04-26 | 2023-12-22 | キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US11613573B2 (enExample) |
| EP (2) | EP3615046A4 (enExample) |
| JP (4) | JP7538601B2 (enExample) |
| KR (3) | KR102729668B1 (enExample) |
| CN (2) | CN110741016A (enExample) |
| AU (3) | AU2018258045B2 (enExample) |
| CA (2) | CA3059755A1 (enExample) |
| IL (4) | IL321897A (enExample) |
| MX (1) | MX2024007576A (enExample) |
| PH (1) | PH12019502411A1 (enExample) |
| SG (5) | SG11201909541WA (enExample) |
| TW (4) | TWI882944B (enExample) |
| WO (3) | WO2018200585A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL303905A (en) | 2015-05-18 | 2023-08-01 | Tcr2 Therapeutics Inc | Compositions and methods for TCR programming using fusion proteins |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| ES2875959T3 (es) | 2016-10-07 | 2021-11-11 | Tcr2 Therapeutics Inc | Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión |
| AU2017363311A1 (en) | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| AU2018258045B2 (en) | 2017-04-26 | 2024-02-29 | Eureka Therapeutics, Inc. | Chimeric antibody/T-cell receptor constructs and uses thereof |
| EP3774919A4 (en) * | 2018-03-30 | 2021-12-29 | Eureka Therapeutics, Inc. | Constructs targeting cd22 and uses thereof |
| SG11202012342WA (en) | 2018-06-18 | 2021-01-28 | Eureka Therapeutics Inc | Constructs targeting prostate-specific membrane antigen (psma) and uses thereof |
| WO2020023888A2 (en) * | 2018-07-26 | 2020-01-30 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using target specific fusion proteins |
| EP3670530A1 (en) * | 2018-12-18 | 2020-06-24 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies |
| CN111100199B (zh) * | 2018-12-29 | 2021-02-12 | 北京百普赛斯生物科技股份有限公司 | 一种荧光素标记的蛋白四聚体及其制备方法与应用 |
| CA3126422A1 (en) * | 2019-01-14 | 2020-07-23 | Nanjing Legend Biotech Co., Ltd. | Chimeric receptor polypeptides and uses thereof |
| JP7261307B2 (ja) * | 2019-01-28 | 2023-04-19 | ウーシー バイオロジクス アイルランド リミテッド | 新規二重特異性ｃｄ３／ｃｄ２０ポリペプチド複合体 |
| US20220127372A1 (en) * | 2019-02-01 | 2022-04-28 | Cafa Therapeutics Limited | Tcr fusion protein and cell expressing tcr fusion protein |
| PE20220649A1 (es) * | 2019-07-26 | 2022-04-28 | Janssen Biotech Inc | Proteinas que comprenden dominios de union al antigeno de la peptidasa 2 relacionada con la calicreina y sus usos |
| JP2023516067A (ja) * | 2020-03-02 | 2023-04-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | がんの処置のためのキメラ抗原受容体ならびに関連した方法および組成物 |
| IL296411A (en) * | 2020-03-16 | 2022-11-01 | Univ Southern California | Novel antigen binding domains and synthetic antigen receptors incorporating them |
| BR112022018491A2 (pt) | 2020-03-20 | 2022-11-29 | Lyell Immunopharma Inc | Marcadores de superfície celular recombinante |
| EP4127188A4 (en) | 2020-03-31 | 2024-08-21 | Walking Fish Therapeutics | MODIFIED B CELLS AND METHODS OF USE THEREOF |
| MX2022012295A (es) * | 2020-03-31 | 2023-03-06 | Walking Fish Therapeutics | Celulas b modificadas y metodos de uso de las mismas. |
| CN112830973B (zh) * | 2020-04-08 | 2022-11-01 | 苏州克睿基因生物科技有限公司 | 嵌合多肽及其用途 |
| KR20230017786A (ko) | 2020-04-28 | 2023-02-06 | 라이엘 이뮤노파마, 인크. | 세포 배양 방법 |
| US20240148869A1 (en) * | 2020-05-07 | 2024-05-09 | China Immunotech (Beijing) Biotechnology Co., Ltd | Improved T cell receptor-costimulatory molecule chimera |
| CA3185145A1 (en) * | 2020-05-25 | 2021-12-02 | Bristar Immunotech Limited | Enhanced synthetic t cell receptor and antigen receptor |
| CN116348485A (zh) | 2020-07-17 | 2023-06-27 | 英研生物(英国)有限公司 | 提供用于过继性细胞疗法的靶向共刺激的受体 |
| EP4189072A4 (en) * | 2020-07-29 | 2024-09-18 | Eureka Therapeutics, Inc. | T-CELLS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF |
| CN116997563A (zh) | 2021-01-27 | 2023-11-03 | 莱尔免疫制药股份有限公司 | 改良的免疫细胞疗法 |
| CN114957481A (zh) * | 2021-02-25 | 2022-08-30 | 华夏英泰（北京）生物技术有限公司 | 针对cd19和cd22的双靶点star |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| US20240228957A9 (en) | 2021-02-25 | 2024-07-11 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| WO2022182890A1 (en) | 2021-02-25 | 2022-09-01 | Lyell Immunopharma, Inc. | Codon-optimized nucleotide sequences encoding an ap-1 transcription factor |
| EP4347826A1 (en) | 2021-06-02 | 2024-04-10 | Lyell Immunopharma, Inc. | Nr4a3-deficient immune cells and uses thereof |
| TW202306997A (zh) | 2021-06-16 | 2023-02-16 | 英商英斯特生物科技有限公司 | 用於在過繼細胞療法中提供標靶共刺激之受體 |
| WO2023288278A1 (en) | 2021-07-16 | 2023-01-19 | Instil Bio (Uk) Limited | Chimeric molecules providing targeted costimulation for adoptive cell therapy |
| AU2022317127B2 (en) * | 2021-07-29 | 2025-02-27 | Nantcell, Inc. | Modified t cell receptors for the prevention and treatment of viral infections and cancer |
| EP4419544A1 (en) | 2021-10-21 | 2024-08-28 | Lyell Immunopharma, Inc. | Enhanced immune cell therapy |
| IL312302A (en) | 2021-10-28 | 2024-06-01 | Lyell Immunopharma Inc | Methods for creating cells |
| JP2024540099A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法 |
| CA3234826A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing c-jun |
| WO2023133540A1 (en) | 2022-01-07 | 2023-07-13 | Lyell Immunopharma, Inc. | Il-12 affinity variants |
| CN114591443A (zh) * | 2022-03-07 | 2022-06-07 | 皖南医学院第一附属医院（皖南医学院弋矶山医院） | 一种基于scTv的嵌合受体CSR及其应用 |
| WO2023215738A1 (en) | 2022-05-02 | 2023-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions targeting gpc2 and gpc3 and their use for treating solid tumors |
| AU2023273885A1 (en) | 2022-05-19 | 2024-12-05 | Lyell Immunopharma, Inc. | Polynucleotides targeting nr4a3 and uses thereof |
| WO2024020429A1 (en) | 2022-07-22 | 2024-01-25 | Lyell Immunopharma, Inc. | Immune cell therapy |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| WO2024148369A1 (en) | 2023-01-07 | 2024-07-11 | Lyell Immunopharma, Inc. | Targeted il-12 affinity variants |
| WO2024182539A1 (en) | 2023-02-28 | 2024-09-06 | Lyell Immunopharma, Inc. | Methods of culturing reprogrammed cells |
| WO2025006797A1 (en) | 2023-06-27 | 2025-01-02 | Lyell Immunopharma, Inc. | Il-12 stability variants |
| WO2025024559A1 (en) | 2023-07-24 | 2025-01-30 | Strand Therapeutics Inc. | Rna-based synthetic circuit for producing engineered immune cells for an extracorporeal cell therapy |
| EP4520346A1 (en) | 2023-09-06 | 2025-03-12 | Gyncentrum Sp. z o.o. | Cells, methods and systems for use in the treatment of a cancer with dual-car-t |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (149)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3753357A (en) | 1970-12-14 | 1973-08-21 | Ovitron Res Corp | Method and apparatus for the preservation of cells and tissues |
| US4199022A (en) | 1978-12-08 | 1980-04-22 | The United States Of America As Represented By The Department Of Energy | Method of freezing living cells and tissues with improved subsequent survival |
| US4559298A (en) | 1982-11-23 | 1985-12-17 | American National Red Cross | Cryopreservation of biological materials in a non-frozen or vitreous state |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL86278A (en) | 1988-05-04 | 2003-06-24 | Yeda Res & Dev | Endowing cells with antibody specificity using chimeric t cell receptor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| GB9221657D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
| US5585358A (en) | 1993-07-06 | 1996-12-17 | Yissum Research Development Corporation Of The Hebrew University Of Jerusalem | Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| JPH11510375A (ja) | 1995-06-30 | 1999-09-14 | コベンハブンズ ユニバーサイテッド | ペプチド−ｍｈｃ複合体を指向するファージディスプレイライブラリーからの組換え抗体 |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| JP2003516124A (ja) | 1999-10-15 | 2003-05-13 | ユニバーシティー オブ マサチューセッツ | 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| EP1240319A1 (en) | 1999-12-15 | 2002-09-18 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| HK1047770A1 (zh) | 2000-02-24 | 2003-03-07 | Xcyte Therapies, Inc. | 细胞的同时刺激与浓缩 |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| JP5312721B2 (ja) | 2000-11-07 | 2013-10-09 | シティ・オブ・ホープ | Ｃｄ１９特異的再指向免疫細胞 |
| JP2005512044A (ja) | 2001-12-03 | 2005-04-28 | アブジェニックス・インコーポレーテッド | 結合特性に基づく抗体分類 |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| CA2523716C (en) | 2003-05-31 | 2014-11-25 | Micromet Ag | Human anti-human cd3 binding molecules |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| CA2567814C (en) | 2004-05-27 | 2013-07-23 | Jon A. Weidanz | Antibodies as t cell receptor mimics, methods of production and uses thereof |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| KR20080032097A (ko) | 2005-06-20 | 2008-04-14 | 메다렉스, 인코포레이티드 | 씨디19 항체 및 그의 용도 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| JP2009508517A (ja) | 2005-09-22 | 2009-03-05 | コーエン，イルン，アール | Ｔ細胞受容体定常ドメインの免疫原性断片及びそれに由来するペプチド |
| ES2577292T3 (es) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso |
| US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| MX2008013705A (es) | 2006-04-28 | 2008-11-06 | Esbatech Ag | Anticuerpos que se enlazan al dominio extracelular de la cinasa de linfoma anaplastico del receptor tirosina cinasa. |
| EP2016102B1 (en) | 2006-05-03 | 2012-03-21 | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services | Chimeric t cell receptors and related materials and methods of use |
| EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| WO2007143104A2 (en) | 2006-06-01 | 2007-12-13 | Receptor Logic, Ltd. | Antibodies as t cell receptor mimics, methods of production and uses thereof |
| MX2009002414A (es) | 2006-09-08 | 2009-05-20 | Medimmune Llc | Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria. |
| US8629245B2 (en) | 2007-05-01 | 2014-01-14 | Research Development Foundation | Immunoglobulin Fc libraries |
| AU2008251608B2 (en) | 2007-05-08 | 2014-03-27 | Genentech, Inc. | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| CN105002189A (zh) | 2008-06-25 | 2015-10-28 | 阿森尼克斯公司 | 毒素基因及其使用方法 |
| TWI543767B (zh) | 2008-08-19 | 2016-08-01 | 腫瘤療法 科學股份有限公司 | Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗 |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| US20110286916A1 (en) | 2008-11-20 | 2011-11-24 | Jose Miguel Aste-Amezaga | Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use |
| US20100153133A1 (en) | 2008-12-16 | 2010-06-17 | International Business Machines Corporation | Generating Never-Event Cohorts from Patient Care Data |
| US20110311517A1 (en) | 2009-02-10 | 2011-12-22 | Shenogen Pharma Group, Ltd. | Antibodies and methods for treating estrogen receptor-associated diseases |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| AU2010277561A1 (en) | 2009-07-30 | 2012-02-09 | Helmholtz-Zentrum Fur Infektionsforschung Gmbh | Compositions for generating an antigen specific immune response |
| AU2010309438A1 (en) | 2009-10-22 | 2012-06-07 | Ricardo J. Moro | Peptides that bind the alpha-fetoprotein (AFP) receptor and uses thereof |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| HUE032519T2 (en) | 2010-03-26 | 2017-09-28 | Memorial Sloan Kettering Cancer Center | Antibodies to muc16 and methods of use thereof |
| WO2012050374A2 (en) | 2010-10-13 | 2012-04-19 | Innocell, Inc. | Immunotherapy for solid tumors |
| WO2015070078A1 (en) | 2013-11-07 | 2015-05-14 | Memorial Sloan-Kettering Cancer Center | Fc-enhanced anti-wt1/hla antibody |
| AU2012236068A1 (en) | 2011-04-01 | 2013-10-17 | Eureka Therapeutics, Inc. | T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2 |
| US10239952B2 (en) | 2011-04-01 | 2019-03-26 | Memorial Sloan Kettering Cancer Center | Anti-WT1/HLA bi-specific antibody |
| US20130280220A1 (en) * | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| CA2871417C (en) | 2012-04-23 | 2021-08-31 | Genefrontier Corporation | Anti-human cd69 antibody, and use thereof for medical purposes |
| CN103319595B (zh) | 2012-07-04 | 2016-12-28 | 中国药科大学 | 抗人afp单链抗体以及融合抗原肽的制备方法和应用 |
| EP2872526B1 (en) * | 2012-07-13 | 2020-04-01 | The Trustees of the University of Pennsylvania | Enhancing activity of car t cells by co-introducing a bispecific antibody |
| US20150183877A1 (en) | 2012-07-18 | 2015-07-02 | Eli Lilly And Company | Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains |
| RU2663725C2 (ru) | 2012-09-04 | 2018-08-08 | Селлектис | Многоцепочечный химерный антигенный рецептор и его применения |
| CN104853766A (zh) * | 2012-10-02 | 2015-08-19 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| CN102993305B (zh) | 2012-11-16 | 2015-05-13 | 上海赛伦生物技术有限公司 | 人源抗人表皮生长因子受体抗体及其编码基因与应用 |
| WO2014093855A1 (en) | 2012-12-13 | 2014-06-19 | University Of Virginia Patent Foundation | Target peptides for ovarian cancer therapy and diagnostics |
| WO2014123165A1 (ja) | 2013-02-06 | 2014-08-14 | 旭硝子株式会社 | 透明面材およびそれを用いた表示装置 |
| CN103965362B (zh) | 2013-02-06 | 2019-02-01 | 上海细胞治疗集团有限公司 | 一种可使t细胞趋向肿瘤部位的嵌合趋化因子受体 |
| MX378463B (es) | 2013-02-26 | 2025-03-10 | Memorial Sloan Kettering Cancer Center | Composiciones y usos de las mismas para inmunoterapia. |
| WO2014152878A2 (en) | 2013-03-14 | 2014-09-25 | Agrivida, Inc. | Use of dimerization domains for temperature regulation of enzyme activity |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| US9937207B2 (en) | 2013-03-21 | 2018-04-10 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell receptor genes using talens |
| KR101536668B1 (ko) | 2013-06-18 | 2015-07-15 | 사회복지법인 삼성생명공익재단 | 인간 및 마우스 c-Met에 교차결합하는 항체 및 그의 용도 |
| GB201313377D0 (en) | 2013-07-26 | 2013-09-11 | Adaptimmune Ltd | T cell receptors |
| CA2956667A1 (en) | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
| WO2015063069A1 (en) | 2013-10-28 | 2015-05-07 | Benjamin Felder | Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors |
| ES2742224T3 (es) | 2013-11-07 | 2020-02-13 | Memorial Sloan Kettering Cancer Center | Anticuerpos biespecíficos anti-WT1/HLA |
| MA39502A (fr) * | 2014-02-28 | 2015-09-03 | Glenmark Pharmaceuticals Sa | Constructions d'expression et méthodes de sélection des cellules hôtes exprimant des polypeptides |
| CN104087592B (zh) | 2014-05-13 | 2016-01-27 | 天津医科大学总医院 | Afp158-166特异性tcr基因及其转基因t细胞及体外增殖方法及用途 |
| SG11201701309SA (en) | 2014-09-15 | 2017-04-27 | Molmed Spa | Chimeric antigen receptors |
| US20190030071A1 (en) | 2014-11-03 | 2019-01-31 | IMMURES S.r.I. | T cell receptors |
| JP7174522B2 (ja) | 2014-12-05 | 2022-11-17 | メモリアル スローン ケタリング キャンサー センター | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
| PL3226897T3 (pl) | 2014-12-05 | 2021-08-30 | Memorial Sloan Kettering Cancer Center | Przeciwciała do celowania w antygen dojrzewania limfocytów b i sposoby ich zastosowania |
| CN113429484A (zh) | 2014-12-05 | 2021-09-24 | 纪念斯隆-凯特琳癌症中心 | 靶向g-蛋白偶联受体的抗体和使用方法 |
| KR20240130831A (ko) | 2014-12-05 | 2024-08-29 | 메모리얼 슬로안 케터링 캔서 센터 | B-세포 성숙화 항원을 표적화하는 키메라 항원 수용체 및 그의 용도 |
| CN113683711A (zh) | 2014-12-05 | 2021-11-23 | 纪念斯隆-凯特琳癌症中心 | 靶向g-蛋白偶联受体的嵌合抗原受体及其用途 |
| US11673957B2 (en) | 2015-03-10 | 2023-06-13 | Eureka Therapeutics, Inc. | Anti-ROR2 antibodies |
| RU2758113C2 (ru) | 2015-03-17 | 2021-10-26 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Антитела к muc16 и их применение |
| WO2016149578A1 (en) | 2015-03-19 | 2016-09-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dual specific anti-cd22-anti-cd19 chimeric antigen receptors |
| WO2016154047A2 (en) | 2015-03-20 | 2016-09-29 | Memorial Sloan-Kettering Cancer Center | Monoclonal antigen-binding proteins to intracellular oncogene products |
| RU2021124437A (ru) | 2015-04-03 | 2021-09-29 | Еурека Терапьютикс, Инк. | Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования |
| SG11201708674XA (en) | 2015-05-08 | 2017-11-29 | Eureka Therapeutics Inc | Constructs targeting hpv16-e7 peptide/mhc complexes and uses thereof |
| IL303905A (en) | 2015-05-18 | 2023-08-01 | Tcr2 Therapeutics Inc | Compositions and methods for TCR programming using fusion proteins |
| EP3297671A4 (en) | 2015-05-18 | 2019-02-06 | Eureka Therapeutics, Inc. | ANTI-ROR1 ANTIBODY |
| EP3298032A1 (en) | 2015-05-18 | 2018-03-28 | Bluebird Bio, Inc. | Anti-ror1 chimeric antigen receptors |
| TW201702272A (zh) | 2015-05-22 | 2017-01-16 | 美國紀念斯隆 凱特琳癌症中心 | Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體 |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| IL281396B (en) | 2015-06-09 | 2022-07-01 | Memorial Sloan Kettering Cancer Center | T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla |
| CN117387731A (zh) | 2015-06-12 | 2024-01-12 | 美蓓亚三美株式会社 | 载荷检测器和载荷检测系统 |
| HK1254803A1 (zh) | 2015-06-23 | 2019-07-26 | Memorial Sloan Kettering Cancer Center | 新型pd -1的免疫调节剂 |
| CN107922471A (zh) | 2015-06-24 | 2018-04-17 | 优瑞科生物技术公司 | 靶向ny‑eso‑1肽/mhc复合物的构建体及其用途 |
| WO2017004252A1 (en) | 2015-06-30 | 2017-01-05 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Redirected cells with mhc chimeric receptors and methods of use in immunotherapy |
| KR20180029253A (ko) | 2015-07-22 | 2018-03-20 | 유레카 쎄라퓨틱스, 인코포레이티드 | Psa 펩티드/mhc 복합체를 표적화하는 구축물 및 그의 용도 |
| EP3331913A1 (en) * | 2015-08-07 | 2018-06-13 | Novartis AG | Treatment of cancer using chimeric cd3 receptor proteins |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| WO2017044699A1 (en) | 2015-09-10 | 2017-03-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd276 chimeric antigen receptors |
| HK1250517A1 (zh) | 2015-09-17 | 2018-12-21 | Novartis Ag | 增强功效的car t细胞疗法 |
| SG11201803054UA (en) | 2015-10-13 | 2018-05-30 | Eureka Therapeutics Inc | Antibody agents specific for human cd19 and uses thereof |
| MX2018004721A (es) * | 2015-10-23 | 2018-07-06 | Eureka Therapeutics Inc | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. |
| CN105331585A (zh) | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| WO2017096120A1 (en) | 2015-12-04 | 2017-06-08 | Memorial Sloan-Kettering Cancer Center | Antibodies targeting fc receptor-like 5 and methods of use |
| MX2018008416A (es) | 2016-01-08 | 2019-11-11 | Univ California | Polipéptidos heterodímericos condicionalmente activos y métodos para su uso. |
| US11505599B2 (en) | 2016-01-14 | 2022-11-22 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like antibodies specific for Foxp3-derived peptides |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| WO2018057967A2 (en) | 2016-09-23 | 2018-03-29 | Eureka Therapeutics, Inc. | Constructs targeting hiv peptide/mhc complexes and uses thereof |
| ES2875959T3 (es) | 2016-10-07 | 2021-11-11 | Tcr2 Therapeutics Inc | Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión |
| AU2017363311A1 (en) | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| EP3558348A1 (en) | 2016-12-21 | 2019-10-30 | TCR2 Therapeutics Inc. | Engineered t cells for the treatment of cancer |
| EP3579877A4 (en) | 2017-02-09 | 2020-12-09 | The Regents of The University of California | CHEMERIC T-LYMPHOCYTE ANTIGENIC RECEPTORS AND METHODS OF USE |
| AU2018258049B2 (en) | 2017-04-26 | 2025-03-27 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
| AU2018258045B2 (en) | 2017-04-26 | 2024-02-29 | Eureka Therapeutics, Inc. | Chimeric antibody/T-cell receptor constructs and uses thereof |
| WO2018232020A1 (en) | 2017-06-13 | 2018-12-20 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| EP3774919A4 (en) | 2018-03-30 | 2021-12-29 | Eureka Therapeutics, Inc. | Constructs targeting cd22 and uses thereof |
| SG11202012342WA (en) | 2018-06-18 | 2021-01-28 | Eureka Therapeutics Inc | Constructs targeting prostate-specific membrane antigen (psma) and uses thereof |
| EP4640698A2 (en) | 2018-11-16 | 2025-10-29 | Memorial Sloan Kettering Cancer Center | Antibodies to mucin-16 and methods of use thereof |
| WO2020227538A1 (en) | 2019-05-08 | 2020-11-12 | Memorial Sloan Kettering Cancer Center | Humanized antibodies to mucin-16 and methods of use thereof |
| KR20220045155A (ko) | 2019-07-24 | 2022-04-12 | 유레카 쎄라퓨틱스, 인코포레이티드 | 키메라 항원 수용체 및 키메라 자극 수용체를 발현하는 세포 및 이의 용도 |
| EP4189072A4 (en) | 2020-07-29 | 2024-09-18 | Eureka Therapeutics, Inc. | T-CELLS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF |
-
2018
- 2018-04-24 AU AU2018258045A patent/AU2018258045B2/en active Active
- 2018-04-24 US US16/608,336 patent/US11613573B2/en active Active
- 2018-04-24 WO PCT/US2018/029220 patent/WO2018200585A1/en not_active Ceased
- 2018-04-24 JP JP2019558623A patent/JP7538601B2/ja active Active
- 2018-04-24 US US16/608,366 patent/US11965021B2/en active Active
- 2018-04-24 JP JP2019558421A patent/JP2020517287A/ja active Pending
- 2018-04-24 SG SG11201909541W patent/SG11201909541WA/en unknown
- 2018-04-24 IL IL321897A patent/IL321897A/en unknown
- 2018-04-24 WO PCT/US2018/029217 patent/WO2018200582A1/en not_active Ceased
- 2018-04-24 SG SG10201913655UA patent/SG10201913655UA/en unknown
- 2018-04-24 AU AU2018258046A patent/AU2018258046C1/en active Active
- 2018-04-24 KR KR1020197034683A patent/KR102729668B1/ko active Active
- 2018-04-24 CN CN201880027809.XA patent/CN110741016A/zh active Pending
- 2018-04-24 SG SG10201913656TA patent/SG10201913656TA/en unknown
- 2018-04-24 WO PCT/US2018/029218 patent/WO2018200583A1/en not_active Ceased
- 2018-04-24 CA CA3059755A patent/CA3059755A1/en active Pending
- 2018-04-24 EP EP18791852.9A patent/EP3615046A4/en active Pending
- 2018-04-24 US US16/608,362 patent/US20210093666A1/en not_active Abandoned
- 2018-04-24 EP EP18789935.6A patent/EP3615567A4/en active Pending
- 2018-04-24 CA CA3059753A patent/CA3059753A1/en active Pending
- 2018-04-24 SG SG11201909571S patent/SG11201909571SA/en unknown
- 2018-04-24 IL IL270136A patent/IL270136B2/en unknown
- 2018-04-24 CN CN201880027849.4A patent/CN110662547A/zh active Pending
- 2018-04-24 IL IL310182A patent/IL310182A/en unknown
- 2018-04-24 KR KR1020197034684A patent/KR102762834B1/ko active Active
- 2018-04-24 SG SG10201913579WA patent/SG10201913579WA/en unknown
- 2018-04-24 KR KR1020257003114A patent/KR20250022233A/ko active Pending
- 2018-04-26 TW TW107114322A patent/TWI882944B/zh active
- 2018-04-26 TW TW114103778A patent/TW202521690A/zh unknown
- 2018-04-26 TW TW107114337A patent/TWI874297B/zh active
- 2018-04-26 TW TW107114336A patent/TW201902936A/zh unknown
-
2019
- 2019-10-09 MX MX2024007576A patent/MX2024007576A/es unknown
- 2019-10-22 US US16/660,515 patent/US10822413B2/en active Active
- 2019-10-24 IL IL270161A patent/IL270161B2/en unknown
- 2019-10-24 PH PH12019502411A patent/PH12019502411A1/en unknown
-
2023
- 2023-03-28 JP JP2023051860A patent/JP2023093472A/ja active Pending
- 2023-12-22 JP JP2023216495A patent/JP2024038039A/ja not_active Withdrawn
-
2024
- 2024-02-15 AU AU2024200970A patent/AU2024200970A1/en not_active Abandoned
- 2024-03-01 US US18/593,621 patent/US20240317855A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517295A5 (enExample) | ||
| HRP20231542T1 (hr) | Kimerni antigenski receptori koji ciljaju bcma i postupci njihove uporabe | |
| JP2021094037A5 (enExample) | ||
| JP2021087455A5 (enExample) | ||
| JP2025028239A5 (enExample) | ||
| FI4324851T3 (fi) | BCMA-spesifisiä kimeerisiä antigeenireseptoreita ja niiden käyttöjä | |
| JP2020533958A5 (enExample) | ||
| JP2019527557A5 (enExample) | ||
| JP2025065142A5 (enExample) | ||
| JP2017524367A5 (enExample) | ||
| JP2021500881A5 (enExample) | ||
| JP2020114264A5 (enExample) | ||
| JP2018525033A5 (enExample) | ||
| EP4148125A1 (en) | Engineered immune cell for allotransplantation | |
| RU2018109426A (ru) | Химерные антигенные рецепторы со встроенными контролируемыми функциями | |
| HRP20211978T1 (hr) | Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe | |
| JP2018535701A5 (enExample) | ||
| JP2020511136A5 (enExample) | ||
| JP2020529970A5 (enExample) | ||
| JP2018504094A5 (enExample) | ||
| WO2012079000A4 (en) | Use of chimeric antigen receptor-modified t cells to treat cancer | |
| JP2020513754A5 (enExample) | ||
| JP2018527014A5 (enExample) | ||
| CN115916833A (zh) | 靶向b7h3的抗原结合多肽及其应用 | |
| IL274806B1 (en) | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof |